Effects of an 8‐week high‐dose vitamin D supplementation on fatigue and neuropsychiatric manifestations in post‐ COVID syndrome: A randomized controlled trial
Psychiatry and Clinical Neurosciences · 2024
DOI: 10.1111/pcn.13716 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Psychiatry and Clinical Neurosciences, 2024. Verfasst von Veevarin Charoenporn und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Thammasat University, Pathumthani, Thailand. Hauptthemen laut MEDLINE: Fatigue, Vitamin D, COVID-19, Dietary Supplements. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 86 Literaturangaben. Gefördert von: Thammasat University, Royal College of Psychiatrists of Thailand.
Abstract (Originalsprache)
Aim
This study evaluated the effectiveness of high‐dose vitamin D supplementation in alleviating fatigue and neuropsychiatric symptoms in post‐COVID syndrome.
Methods
In an 8‐week, double‐blind, randomized, placebo‐controlled trial, 80 patients with post‐COVID fatigue or neuropsychiatric symptoms were enrolled. Participants were randomly assigned to receive either 60,000 IU of vitamin D weekly ( n = 40) or a placebo ( n = 40) for 8 weeks. Clinical outcomes were assessed using the 11‐item Chalder Fatigue Scale (CFQ‐11); 21‐item Depression, Anxiety, and Stress Scale (DASS‐21); Pittsburgh Sleep Quality Index (PSQI); Addenbrooke's Cognitive Examination III (ACE); and Trail Making Test A and B (TMT‐A and TMT‐B). Baseline and 8‐week measurements of inflammatory markers, including interleukin 6 (IL‐6) and C‐reactive protein (CRP), were also collected.
Results
Significant improvements were found in the vitamin D group for CFQ (coefficient −3.5, P = 0.024), DASS‐anxiety (−2.0, P = 0.011), and ACE (2.1, P = 0.012). No significant differences were observed in PSQI, DASS‐depression, TMT, IL‐6, or CRP levels. The incidence of adverse events was comparable between groups, with no serious adverse events reported.
Conclusion
High‐dose vitamin D supplementation may benefit patients with post‐COVID syndrome by reducing fatigue, alleviating anxiety, and improving cognitive symptoms, with minimal side effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Thammasat University, Pathumthani, Thailand.
- Department of Psychiatry, Thammasat University Hospital, Pathumthani, Thailand.
- Chulabhorn International College of Medicine, Thammasat University, Pathumthani, Thailand.
- Medical student, Faculty of Medicine, Thammasat University, Pathumthani, Thailand.
- Division of Health and Applied Sciences, Faculty of Science, Prince of Songkla University, Songkhla, Thailand.
- Center of Excellence in Applied Epidemiology, Thammasat University, Pathumthani, Thailand.
ORCID-Profile: Veevarin Charoenporn
Förderung
- Thammasat University
- Royal College of Psychiatrists of Thailand
Zitieren
APA
Charoenporn, V., Tungsukruthai, P., Teacharushatakit, P., Hanvivattanakul, S., Sriyakul, K., Sukprasert, S., Kamalashiran, C., Tungsukruthai, S., & Charernboon, T. (2024). Effects of an 8‐week high‐dose vitamin D supplementation on fatigue and neuropsychiatric manifestations in post‐ COVID syndrome: A randomized controlled trial. Psychiatry and Clinical Neurosciences. https://doi.org/10.1111/pcn.13716
Vancouver
Charoenporn V, Tungsukruthai P, Teacharushatakit P, Hanvivattanakul S, Sriyakul K, Sukprasert S, et al. Effects of an 8‐week high‐dose vitamin D supplementation on fatigue and neuropsychiatric manifestations in post‐ COVID syndrome: A randomized controlled trial. Psychiatry and Clinical Neurosciences. 2024. doi:10.1111/pcn.13716
BibTeX
@article{Charoenporn2024,
author = {Charoenporn, Veevarin and Tungsukruthai, Parunkul and Teacharushatakit, Pitchapa and Hanvivattanakul, Sirashat and Sriyakul, Kusuma and Sukprasert, Sophida and Kamalashiran, Chuntida and Tungsukruthai, Sucharat and Charernboon, Thammanard},
title = {Effects of an 8‐week high‐dose vitamin D supplementation on fatigue and neuropsychiatric manifestations in post‐ COVID syndrome: A randomized controlled trial},
journal = {Psychiatry and Clinical Neurosciences},
year = {2024},
doi = {10.1111/pcn.13716}
}
EUVIMED